.
In the past few years, multiple genome-wide association (GWA) studies have detected over a dozen germline SNPs that are each associated with a modest increase in the risk of prostate cancer [2] [3] [4] [5] [6] [7] [8] [9] [10] . In combination these SNPs might result in substantially higher risk among the limited proportion of men who carry large numbers of variants.
In parallel with this wave of GWA studies, expression array studies have identified numerous somatic mutations in prostate tumours, including chromosomal rearrangements and recurrent gene fusions. The most common gene fusion in prostate cancer is between the transmembrane protease serine 2 (TMPRSS2) and ERG, a member of the erythroblast-transformation specific (ETS) gene family; this fusion has been observed in approximately 50% of the tumours studied [11] [12] [13] . This finding and other studies have distinguished combinations of gene expression patterns that might predict prostate cancer aggressiveness.
Here we consider how these GWA studies and expression array results refine our understanding of prostate cancer genetics, and the implications of these findings on screening and treatment for this disease. In addition, we discuss how these results can be further clarified by future research, translated to clinical practice and provide general lessons that are valuable for the study of any phenotype.
The search for germline risk alleles
In the developed world, prostate cancer is the most common non-skin cancer among men. Widely agreed upon risk factors for prostate cancer include age, ethnicity and a family history of this disease 1 . In an attempt to explain the hereditary basis of prostate cancer, extensive candidate gene studies and linkage analyses have been undertakenalbeit with predominantly equivocal results. Although focused candidate gene studies have detected many associations with prostate cancer, most of these have been poorly replicated 1 .
' Agnostic' genome-wide approaches such as linkage analyses and GWA studies enable us to exhaustively search for prostate cancer loci without having to specify particular candidate genes. Linkage analysis is best suited to studying rare variants with high penetrance. Much of the genetic basis of prostate cancer, however, is believed to arise from multiple low-risk genes. This could explain why linkage analyses of prostate cancer have detected few highly replicated loci 14 . By contrast, GWA studies can provide greater power to detect small to modest effects on disease risk 15, 16 .
GWA studies finally yield results
There has been a rapid increase in the number of published GWA studies, including multiple prostate cancer studies that identified over a dozen highly replicated independent germline loci for disease [2] [3] [4] [5] [6] [7] [8] [9] [10] . -8 -we have used this cut-off point to focus on the most compelling results. Note that a number of different p value cut-off points have been used to assess 'statistical significance' in GWA studies; for example, from p < 5 × 10 -7 to p < 1 × 10 -9 . However, one should be careful not to disregard results simply because they fall outside of a p value cut-off point, as they could still be causal for disease 17 . One of the most striking findings is that at least three distinct loci within a ~1 Mb segment of chromosome 8q24 harbour germline variants that are associated with prostate cancer [3] [4] [5] . These variants were detected by a combination of linkage studies 18 , admixture studies 19 and association studies [3] [4] [5] [20] [21] [22] [23] [24] , with association studies identifying specific risk alleles. A meta-analysis of the 8q24 findings suggests that the SNPs result in a 25% to 50% increased risk of prostate cancer 25 . SNPs in the 8q24 region have also been associated with colorectal, breast, ovarian and bladder cancers [26] [27] [28] [29] . No known genes reside in the 8q24 region, although the oncogene MYC is approximately 200 kb downstream. However, studies suggest that the 8q24 risk alleles do not affect MYC expression 3, 29 , and consequently the biological mechanisms underlying the 8q24 associations with cancer remains unclear.
In addition, two distinct prostate cancer loci on chromosome 17 were detected across multiple populations; the corresponding variants each increase risk by approximately 20% and are common, with Prostate cancer genomics: towards a new understanding
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[…] studies have distinguished combinations of gene expression patterns that might predict prostate cancer aggressiveness.
minor allele frequencies close to 50% 6, 9, 10, 30 . Interestingly, the chromosome 17q12 prostate cancer risk variant (rs4430796; located in intron 4 of the HNF1 homeobox B gene, HNF1B) also decreases the risk of type 2 diabetes (T2D) by approximately 10% 6 . Moreover, there is an inverse association between T2D and prostate cancer. The HNF1B finding could reflect either pleiotropic effects of the associated SNP or a common mechanism underlying both prostate cancer and T2D, such as a hormonal or metabolic pathway 6 . At present it is unclear how the associated SNP -or another SNP in linkage disequilibrium with rs4430796 -might functionally affect these pathways.
Two loci were also identified on chromosome 10, one of which encompasses a compelling association between a SNP (rs10993994) in the proximal promoter of the β-microseminoprotein gene (MSMB) and prostate cancer 9, 10 . MSMB encodes PSP94 (also known as MSP), a member of the immunoglobulin-binding factor family that promotes apoptosis and decreases tumour vascularization 31 . PSP94 is synthesized by prostate epithelial cells, and is one of the most abundant proteins in the prostate as well as a primary constituent of semen 9 . The associated MSMB SNP (rs10993994) is just 2 bp upstream of the transcription start site, and the risk allele seems to downregulate MSMB expression by approximately 70% 32 . This agrees with the finding that suggests that decreased MSMB expression increases prostate cancer development and progression 31 .
Expression array findings
In addition to germline variants detected by GWA, somatic mutations can be uncovered by expression array analyses of prostate tumours. One of the most exciting results found using expression arrays is that gene fusions are common in tumours 11 . The cancer outlier profile analysis (COPA) bioinformatics approach was used to search for genes that are overexpressed in a subset of prostate tumours; this method found that the 5′ uTr of the androgen-regulated gene TMPRSS2 was fused to ETS family genes, resulting in androgenic induction of oncogenic transcription factor overexpression [11] [12] [13] . A number of somatic rearrangements have been observed, the most common being TMPRSS2-ERG. ERG is a transcriptional regulator, and in vitro studies suggest that ERG overexpression can result in invasive prostate cancer cells 13 . TMPRSS2 and ERG are approximately 3 Mb apart on chromosome 21q22, and the fusion is typically between exon 1 or 2 of TMPRSS2 and exon 2, 3, 4 or 5 of ERG; these fusions could be due to either chromosomal translocations or intrachromosomal deletions 13 . A recent review 13 shows a remarkable trend in the frequency of TMPRSS2-ERG fusions across different samples: 0 in 78 for normal tissue samples; 2 in 84 (2.4%) for benign prostatic hyperplasia samples; 9 in This table summarizes the results presented for sNPs exhibiting replication within or across studies and with association p values less than 5 × 10 -8 . specific sNPs are the most commonly reported; many other sNPs in linkage disequilibrium with these are also associated with prostate cancer. The second allele (+) is associated with an increased risk of prostate cancer. *Most of the results for allele frequencies presented here are for european populations.
‡ Odds ratios correspond to the effect of carrying one additional copy of the risk allele (+).
§ Allele frequencies, odds ratios and p values are from results presented in the initial study (which is listed first in the 'Refs' column) with two exceptions: the p values for the 7p15 and 10q26 sNPs, which are from analyses combining aggressive and non-aggressive prostate cancer cases 9 ; and allele frequencies and odds ratios for the 8q24 loci, which are from a meta-analysis 25 . || The 3p12 sNP (rs2660753) was only marginally associated with prostate cancer in a recent replication study 36 . There is also a compelling sNP on 7p15 (rs10486567; JAZF zinc finger 1, JAZF1) that is associated with prostate cancer, although it has a slightly larger p value (1.2 × 10 -7 ) 9 as well as a recently detected second independently associated sNP in HNF1 homeobox B (HNF1B) 30 . CTBP2, C-terminal binding protein 2; EHBP1, eH domain binding protein 1; KLK, kallikrein-related peptidase; LMTK2, lemur tyrosine kinase 2; MSMB, microseminoprotein-β; NUDT, nucleoside diphosphate linked moiety X-type motif; PsA, prostate-specific antigen; SLC22A3, solute carrier family 22, member 3.
45 (20%) for high-grade prostatic intraepithelial neoplasia samples; and 692 in 1,374 (50%) for clinically localized prostate cancer (that is, tumours confined to the prostate). Interestingly, the TMPRSS2-ERG fusion might activate the MYC oncogene, which is near the 8q24 region that contains multiple GWA SNPs 33 , and might help to improve the prediction of disease risk (for example, beyond that provided by prostate-specific antigen, PSA 34 . TMPRSS2 also fuses to a number of other ETS family genes in prostate tumours, including ETS variant gene 1 (ETV1), ETV4 and ETV5. Additional upstream genes also fuse to these ETS family genes (for example, SLC45A3). However, the ETV fusions seem to account for less than 10% of all tumour fusions 13 ; for example, the frequency of ETV1 fusions in a recent study was 5.4% 35 .
Predicting disease risk with GWA SNPs
The small magnitude of effect for each associated GWA SNP (most odds ratios are less than 1.30) suggests that, taken together, these SNPs might only account for approximately 15% of the familial risk of prostate cancer 10, 36 . Because the corresponding risk-allele frequencies are high, estimates of population attributable risk (PAr) are large (for example, up to 40%). Nonetheless, it is unlikely that the associated SNPs account for such a large percentage of prostate cancer in the general population, especially as they explain little of the heritability.
Each SNP is independently associated with prostate cancer -that is, they do not interact multiplicatively to increase risk beyond the main effect for the individual SNPs. Nevertheless, combinations of these SNPs lead to appreciably increased risk of disease. When considering the distribution of multiple associated SNPs among prostate cancer cases and controls, men in the top decile of risk alleles carried have an approximately two to fourfold increase in risk compared with men in the lowest decile 9, 36, 37 . In light of the increased risk for men who carry multiple risk alleles, some advocate marketing a multiple-SNP screening test for prostate cancer 37 . The increased relative risk, however, does not mean that such a test can sufficiently distinguish between men with low and high risk of disease. In fact, these markers only provide a slight increase in the area under the receiver operating characteristic curve for classifying cases and controls (from 0.61 to 0.63) 37 .
A screening test based on the SNPs detected to date will probably have low positive predictive value and low negative predictive value for prostate cancer, and will have limited usefulness in a diagnostic setting 38 . FIGURE 1 illustrates why using such risk SNPs will predict disease poorly. Adding more SNPs with modest disease associations will do little to improve this situation. Moreover, few men carry large numbers of risk variants, so screening for these in the general population would not be cost-effective.
Another
Markers of prostate cancer aggressiveness
In contrast to using genetic markers to screen non-diseased men, there is clear clinical utility in identifying markers that can distinguish which prostate tumours will progress rapidly and be life-threatening versus those that are relatively latent and might not substantively affect a man's health. This is especially important in light of the considerable co-morbidity and detrimental effects on quality of life arising from the standard treatment options for prostate cancer (that is, surgery or radiotherapy). Although there are a number of existing measures that help determine which men might have more aggressive disease (for example, assessing tumour stage and grade) there remains room for improvement. Moreover, among men that are diagnosed Nature Reviews | Genetics Test cut-off point Figure 1 | Limitations of using multiple associated variants to predict an individual's risk of prostate cancer. The graphs show hypothetical normal distributions of high-risk alleles among cases and controls. a | Recent work suggests that men in the ninetieth percentile of risk-allele counts have a two to fourfold increase in prostate cancer risk compared with men in the tenth percentile. even at the higher end of this range (that is, an odds ratio equal to four), the case and control distributions of high-risk alleles largely overlap. With such a degree of overlap a genetic screening test will perform poorly. For example, although a test based on being in the top decile of risk alleles (above the cut-off point in figure) has 90% specificity (that is, the proportion of true negatives determined by the test) and a negative predictive value (NPV) of 91%, it has only 16% sensitivity (that is, the proportion of true positives determined by the test) and a positive predictive value (PPV) of 15%. Here, the cut-off point is based on the control distribution and the disease prevalence is assumed to equal 10%. b | Using this same genetic test to achieve sufficient separation between the case and control distributions of risk alleles for 90% sensitivity and specificity will require odds ratios substantially larger than those anticipated from GWA studies, even if many sNPs are combined into a single predictor of prostate cancer.
with prostate cancer, there is a sufficiently high risk of progression such that markers for prostate cancer aggressiveness could have reasonable predictive value. For example, if 50% of men progress over time, the positive predictive value would be over 60% (assuming the markers result in a fourfold increase in risk of progression). Some of the germline SNPs detected by GWA studies have been associated with intermediate-or high-risk prostate cancer, although most of these associations were essentially indistinguishable from those observed for less aggressive disease 5, 7, 8, 25 . Moreover, the multiple-SNP model for prediction of disease risk was not associated with disease aggressiveness 37 . This suggests that the germline SNPs detected to date by GWA studies are not risk factors for more aggressive prostate cancer, but instead might primarily initiate disease (FIG. 2) . Detecting aggressivenessassociated variants will require large GWA studies among affected men that search for associations with disease progression (for example, disease recurrence following treatment) or with mortality due to prostate cancer.
With regard to somatic mutations, numerous studies have found that the TMPRSS2-ERG fusion is correlated with more aggressive disease and worse prognosis 13 . Although the frequency of TMPRSS2-ERG fusions decreases slightly for metastatic tumours (23 in 70, 33%), this might simply reflect the small number of tumours studied to date 13 . More recent work suggests that the frequency of fusions is similar in clinically localized and metastatic tumours, but certain subtypes of fusion might be more prevalent in advanced disease 40 . In fact, Kumar-Sinha et al. 13 found that in all metastatic tumours with a TMPRSS2-ERG fusion, the fusion was caused by an interstitial deletion.
Extensive studies of genes that are over and underexpressed in prostate tumours have recently identified 'molecular signatures' for aggressiveness -some of which include the TMPRSS2-ERG fusion [41] [42] [43] . These signatures can contain different sets of genes; although this might seem counterintuitive the finding parallels the situation for breast cancer, in which different expression array-based signatures are highly predictive of prognosis 44 . ultimately, these gene fusion results and expression-array signatures might also help us to distinguish which prostate tumours are more or less likely to progress rapidly, thereby providing valuable information to guide treatment decisions.
Next steps in prostate cancer genomics
Although the recent GWA and expression array studies have made successful steps towards deciphering the genomic basis of prostate cancer, more work is needed to fully understand and apply these findings. Identifying the biological mechanisms underlying the apparent risk variants is essential if we are to advance our understanding of prostate carcinogenesis. Although some of the variants have compelling mechanisms, the role of many others remains unclear and some variants might simply be markers for the true causal factors.
The large number of replicated SNPs from GWA studies is impressive, but many more SNPs will undoubtedly be detected as sample sizes increase and additional populations are studied. So far, almost all of the GWA studies have been undertaken among European Americans. Further studies of minority groups -especially African Americans -will be crucial for deciphering whether the same or different germline SNPs or somatic mutations are important for prostate cancer development and progression among this high-risk population. For example, the 8q24 region seems to harbour some risk variants with different locations and effect sizes (that is, odd ratios) among African-American men 4 . Plans are currently underway for GWA studies of prostate cancer among African Americans in the Multiethnic Cohort and Kaiser Permanente Northern California populations.
The current GWA studies have been undertaken separately from the expression array studies. This is not surprising as GWA studies are focused on germline mutations and expression array studies on somatic mutations. Nevertheless, using both of these approaches in a single study would provide a great opportunity for distinguishing the interrelated nature of Nature Reviews | Genetics Figure 2 | etiologic evolution of prostate cancer and key steps affected by germline variants and somatic fusions. The genome-wide association (GWA) studies that have been undertaken so far have searched for sNPs that affect the progression from normal prostate (controls) to prostate cancer (cases). Numerous highly replicated sNPs for prostate cancer have been detected (for example, on chromosome 8q24). The potential use of these sNPs in differentiating between more and less aggressive disease at diagnosis remains unclear. somatic gene fusions between the transmembrane protease serine 2 gene (TMPRSS2) and members of the erythroblast-transformation specific (eTs) gene family, which includes ERG, have been observed at increasing frequency across the different steps in prostate cancer development. The common TMPRSS2-ERG fusion has similar frequencies among localized and metastatic tumours, although the fusions in metastatic tumours primarily exhibit interstitial deletions. This fusion has been incorporated into gene expression 'signatures' of prostate cancer aggressiveness. Additional studies are needed to more fully distinguish which germline and somatic factors affect the progression of prostate cancer after it is diagnosed; such information could help us to determine the most appropriate treatment among diseased men. MSMB, β-microseminoprotein; HNF1B, HNF1 homeobox B.
these sources of variation. For example, expression array results could be used to distinguish tumour subtypes (for example, those with specific gene fusions), and then GWA results could be used to evaluate germline risks of such subtypes. Studies to determine the potential functional role of associated variants and mutations will also be extremely valuable.
Well-designed studies of disease recurrence following treatment and of mortality owing to prostate cancer are also needed in light of the large phenotypic heterogeneity of this disease. Ideally such studies would evaluate germline SNPs and expression arrays on pre-and post-diagnosis biospecimens, and would include both treated and non-treated men (that is, a 'watchful waiting' group). ultimately, SNP, tumour expression and somatic mutation data could be jointly investigated for their relationship with prognosis and treatment outcomes.
Evaluating such joint data will probably require novel statistical methods and large sample sizes. Moreover, one can speculate that the large number of variants detected by GWA and expression array studies might only act in a limited number of pathways. Although many of the current GWA results for prostate cancer are in genes with suppressor properties, they do not point to a particular pathway (TABLE 1) . Nevertheless, ultimately determining such pathways in prostate cancer might provide an avenue for classifying and treating tumours, especially with regard to disease aggressiveness, and for distinguishing which mutations are drivers and which are passengers in the process of prostate carcinogenesis. Ancillary support for this possibility comes from the recent findings that pancreatic and brain tumours contain hundreds of somatic mutations, many of which are in specific pathways, such as cell signalling 45, 46 .
Lessons learned
The prostate cancer GWA and expression array findings provide some general lessons that are worth considering regardless of the phenotype being studied. First, they underscore the value of agnostic approaches in the search for disease genes. Few of the new findings would have been obtained with focused studies. In a similar vein, these studies also emphasize the importance of undertaking complementary replication and validation studies across multiple populations. Another valuable lesson is that the initial stages of GWA studies will not necessarily pinpoint SNPs that are highly replicated by later stages. For example, the strongly associated SNP in MSMB (rs10993994) had only the 24, 223 rd smallest p value in the initial Cancer Genetic Markers of Susceptibility (CGEMS) GWA study of prostate cancer 9 . This illustrates the importance of large sample sizes, including as many SNPs as feasible in follow-up studies, and of conducting additional GWA studies in diverse populations with well-characterized phenotypes. Moreover, the ranking of SNPs for followup should explicitly incorporate additional information beyond conventional p values (for example, SNP functionality and conservation) 47 . Data and full results from studies should be made available so that others can rapidly evaluate, replicate and combine findings. The CGEMS study has made its results publicly available, and the data from publicly funded GWA studies should be made available to qualified investigators. researchers should be applauded for rapidly publishing all of their results together 10 , as this allows others to replicate findings and to examine phenotypic clustering with particular genetic variants, such as those observed for prostate cancer and T2D 6 . The value of genetic screening hinges on both the predictive value of a test and whether a positive result leads to a worthwhile intervention. Developing a test that can adequately distinguish those with a high risk of a phenotype versus those with a low risk on the basis of GWA results is challenging. The most promising situation might arise for common phenotypes when the predictive value of a test is sufficiently high. Of course, without an advisable intervention there is little justification for genetic testing in the first place.
Finally, although GWA findings should ultimately improve our understanding of the disease process and risks, the resulting estimates of effect might be modest, even for combinations of variants. If so, such findings will explain a limited proportion of disease heritability, regardless of whether the phenotype of interest has high heritability. Nevertheless, this situation might simply reflect the complex multifactoral nature of common diseases such as prostate cancer.
Glossary

Admixture study
An approach for localizing genetic regions that might contain causal variants by correlating the level of individuals' admixture with disease. This type of analysis requires fewer markers than GWA studies, but necessitates a recently admixed population and variation in disease rates across ancestral populations.
Area under the receiver operating characteristic curve (AUC). The receiver operating characteristic curve for a predictor (for example, a genetic test) plots the proportion of cases correctly identified by the test versus the proportion of controls incorrectly classified as cases. The AUC indicates the probability that a factor (for example, a genotype) will predict a higher risk of disease in a randomly selected case than in a control.
Cancer outlier profile analysis (COPA). A method for detecting gene expression pattern outliers in subsets of samples. It is used to distinguish potential oncogenic chromosomal changes.
Expression array study
An examination of the expression of all known genes. This type of analysis is commonly used to determine profiles or 'signatures' of overexpressed and underexpressed genes in diseased versus normal samples.
Genome-wide association (GWA) study
An investigation of the association between common genetic variation and disease. This type of analysis requires a dense set of markers (for example, SNPs) that capture a substantial proportion of common variation across the genome, and large numbers of study subjects.
Linkage analysis
A method for localizing chromosomal regions that harbour causal variants by studying the co-segregation of genetic makers and disease within families. When a marker is commonly observed with the disease, the causal variant might be in the general proximity of the marker.
Negative predictive value
(NPV). The probability that an individual with a negative screening test is truly negative (for example, unaffected).
Population attributable risk
(PAR). The disease incidence in a population that is attributable to a particular risk factor. GWA studies commonly report the PAR percentage to estimate what proportion of the disease is explained by associated variants.
Positive predictive value (PPV). Measures how well a screening or diagnostic test distinguishes true positives: it is the probability that an individual who tests positive is truly positive (for example, affected).
